Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

• Published in: Annals of thoracic medicine 2017-04, Vol.12 (2), p.74-82
• Main Authors: Janahi, Ibrahim Ahmed, Rehman, Abdul, Al-Naimi, Amal Rashid
• Format: Article
• Language: English
• Subjects: Allergic bronchopulmonary aspergillosis; allergic fungal mycosis; Allergies; Allergy; Aspergillosis; Asthma; Care and treatment; Cystic fibrosis; Development and progression; Epidemiology; Estimates; Fungal infections; Immunoglobulins; Monoclonal antibodies; Pathogenesis; Pediatrics; Physiological aspects; Review; Tuberculosis
• ISSN: 1817-1737; 1998-3557
• DOI: 10.4103/atm.ATM_231_16

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder that often occurs in patients with asthma or cystic fibrosis (CF) and is characterized by a hypersensitivity response to the allergens of the fungus . In patients with CF, growth of hyphae within the bronchial lumen triggers an immunoglobulin E (IgE)-mediated hypersensitivity response that results in airway inflammation, bronchospasm, and bronchiectasis. In most published studies, the prevalence of ABPA is about 8.9% in patients with CF. Since the clinical features of this condition overlap significantly with that of CF, ABPA is challenging to diagnose and remains underdiagnosed in many patients. Diagnosis of ABPA in CF patients should be sought in those with evidence of clinical and radiologic deterioration that is not attributable to another etiology, a markedly elevated total serum IgE level (while off steroid therapy) and evidence of sensitization. Management of ABPA involves the use of systemic steroids to reduce inflammation and modulate the immune response. In patients who do not respond to steroids or cannot tolerate them, antifungal agents should be used to reduce the burden of allergens. Recent studies suggest that omalizumab may be an effective option to reduce the frequency of ABPA exacerbations in patients with CF. Further randomized controlled trials are needed to better establish the efficacy of omalizumab in managing patients with CF and ABPA.